C9RANT is a newly discovered protein-like chain that holds great potential promise as a benchmark for measuring disease activity and therapeutic response for patients with the devastating conditions of amyotrophic lateral sclerosis (ALS) and dementia. Mutations within a non-coding region of the C9ORF72 gene are responsible for 20-40% of cases of familial ALS1. This class of mutations generates repetitive, high molecular weight RNA chains which are insoluble and aggregate within the brain as C9RANT accumulations. As with the tau protein in Alzheimer's disease, C9RANT is not found in either healthy people or those with other neurologic diseases.
Immunohistochemistry-Paraffin: C9RANT Antibody
Ash et al published their exciting results on the first identification and characterization of these protein aggregates in Neuron. They used the C9RANT antibody for multiple assays including immunohistochemistry, immunoblotting, and immunofluorescence. Further work must be done to determine if C9RANT is just a biomarker or directly involved in causing cell death and toxicity. Very recent studies in dementia from Dickson’s group at the Mayo Clinic suggest that the clinical and pathological occurrence of C9ORF72 repeats can be further widened and expanded to include other diseases such as progressive amnestic dementia and depressive pseudodementia2,3.
Novus Biologicals offers C9RANT antibodies for your research needs.
PMIDs
